Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

in the placebo group; lung transplantation in 1 patient (1.2%) and 6 patients (7.0%), respectively; and hospitalization for worsening pulmonary arterial hypertension in 8 patients (9.3% ...

The new drug sotatercept stops the remodelling of the pulmonary vessels and even helps patients with advanced pulmonary arterial hypertension (PAH) who have not yet been treated.

A Johns Hopkins Medicine-led analysis of medical information gathered on a diverse group of almost 250,000 people over four ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

Figure 1: Serine elastase inhibition induces survival by reversal of pulmonary hypertension ... were alive at 28 days (only one died in each group). When treated with the elastase inhibitor ...

Pulmonary hypertension is classified into 5 groups based on its cause, according to the American Lung Association: This group includes idiopathic PAH, heritable PAH (due to genetic factors), and ...

Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national ...